EGFR-IN-542 is a novel EGFR inhibitor. EGFR-IN-542 significantly reduces myocardial inflammation, fibrosis, apoptosis and dysfunction. It shows promise for use in the treatment of obesity-induced cardiac complications. References: Peng K, Tian X, Qian Y, et al. Novel EGFR inhibitors attenuate cardiac hypertrophy induced by angiotensin II. Journal of Cellular and Molecular Medicine. 2016;20(3):482-494. doi:10.1111/jcmm.12763.

纯度：≥98%

CAS：1639040-81-5